Innoviva - 21 Year Stock Split History | INVA
Stock split history for Innoviva since 2004. Prices shown are actual historical values and are not adjusted for either splits or dividends. Please see the "Historical Prices" tab for adjusted price values.
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $1.315B | $0.359B |
| Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $873.884B | 42.04 |
| Johnson & Johnson (JNJ) | United States | $449.502B | 17.97 |
| AbbVie (ABBV) | United States | $387.340B | 23.19 |
| Roche Holding AG (RHHBY) | Switzerland | $267.000B | 0.00 |
| Novartis AG (NVS) | Switzerland | $266.905B | 14.15 |
| Merck (MRK) | United States | $214.149B | 9.97 |
| Novo Nordisk (NVO) | Denmark | $203.961B | 11.96 |
| Pfizer (PFE) | United States | $138.902B | 7.63 |
| Sanofi (SNY) | France | $121.941B | 11.71 |
| Bayer (BAYRY) | Germany | $29.748B | 5.61 |